Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progressive decrease of proinsulin secretion in sulphonylurea-treated type 2 diabetes.

Y N Chen1, S Y Chen, L J Zeng

  • 1The Central Laboratory, Guang Zhou Red Cross Hospital, Guang Zhou, 510220, PR China. stcyn@zsu.edu.cn

British Journal of Biomedical Science
|April 9, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Analysis on prediction and mediating effects of triglyceride-glucose body mass index on stroke incidence based on cohort study].

Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi·2026
Same author

Lung transplant evaluation-complications on a timeline.

Clinical radiology·2026
Same author

[Prediction of economic burden caused by thyroid cancer in China, 2025-2034].

Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi·2026
Same author

[A case of peripheral T-cell lymphoma with lung involvement].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases·2025
Same author

[Clinical characteristics and prognostic analysis of 34 patients with primary thyroid lymphoma].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2024
Same author

[Cost-effectiveness of pharmaceutical smoking cessation intervention in China primary cancer prevention].

Zhonghua zhong liu za zhi [Chinese journal of oncology]·2024

Shorter disease duration in type 2 diabetes correlates with higher proinsulin levels and better glucose control. Proinsulin is key for glucose regulation in sulfonylurea-treated patients, but its effect diminishes in treatment failures.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Sulfonylurea (SU) treatment failure in type 2 diabetes is linked to progressive beta-cell dysfunction.
  • Disease duration may reflect the worsening of beta-cell deterioration over time.

Purpose of the Study:

  • To investigate the influence of disease duration on insulin-like molecule secretion and glucose control in SU-treated type 2 diabetes.
  • To assess proinsulin secretion capacity in relation to disease duration and SU treatment response.

Main Methods:

  • Compared two groups of type 2 diabetes patients based on disease duration (<5 years vs. >=5 years).
  • Analyzed glucose, total proinsulin (TPI), intact proinsulin (IPI), and specific insulin (SI) levels during an oral glucose tolerance test.
  • Utilized Homa insulin resistance (IR) index to evaluate insulin resistance.

Related Experiment Videos

Main Results:

  • Patients with shorter disease duration (<5 years) exhibited higher proinsulin (TPI, IPI) levels and lower glucose levels at 2-3 hours.
  • No significant difference in insulin resistance was found between groups.
  • Sulfonylurea responders (SUr) showed lower glucose levels at 0h and 3h compared to SU failures (SUf), irrespective of insulin/proinsulin levels.

Conclusions:

  • Proinsulin plays a significant role in glucose control for type 2 diabetes patients on SU therapy.
  • The impact of proinsulin on glucose control appears reduced in SU failure patients.
  • Disease duration is a critical factor influencing beta-cell function and response to SU treatment.